In the Affirmative, Vol.6, No.5 (Mid-May/Mid-June 1999) by Martin, Mick & The AIDS Project
University of Southern Maine 
USM Digital Commons 
In the Affirmative Periodicals 
5-15-1999 
In the Affirmative, Vol.6, No.5 (Mid-May/Mid-June 1999) 
Mick Martin 
The AIDS Project 
Follow this and additional works at: https://digitalcommons.usm.maine.edu/affirmative 
 Part of the American Studies Commons, Lesbian, Gay, Bisexual, and Transgender Studies Commons, 
and the Public Health Commons 
Recommended Citation 
Martin, Mick and The AIDS Project, "In the Affirmative, Vol.6, No.5 (Mid-May/Mid-June 1999)" (1999). In 
the Affirmative. 20. 
https://digitalcommons.usm.maine.edu/affirmative/20 
This Book is brought to you for free and open access by the Periodicals at USM Digital Commons. It has been 
accepted for inclusion in In the Affirmative by an authorized administrator of USM Digital Commons. For more 
information, please contact jessica.c.hovey@maine.edu. 
Mid-May to Mid-June 
volume VI number V 
.~ 
IN THE AFFIRMATIVE 
a newsletter for Maine's HIV/AIDS community 
IN THIS ISSUE 
Page One 
TAP To March With Pride. 
Page Two 
By The Way, editor Mike Martin's 
monthly column. This month Mike 
goes back to high school. 
Page Three 
The Wellness & You Program, a 
comprehensive health program for 
people living with HIV. 
Page Four 
HIV Medical Science News. 
Page Five 





HIV and Women, HIV Vaccine News, 
and HIV Drug News. 
Page Eight 
Support Groups, Client Services, and 
For Your Information. 
The AIDS Project 
Will Participate 








the G/UB/T Community. THJl 
PROJECT 
by David Aaron Swander 
On Saturday, June 19, 1999, The AIDS Project will be partici-
pating in the Southern Maine Pride Parade in Portland. Our focus 
will be to "thank" the community and the volunteers for all their 
support over the years. The parade will begin at noon in 
Monument Square, heading up Congress Street, down High 
Street and ending in Deering Oaks Park. Those wishing to march 
with TAP employees, board members, and volunteers are encour-
aged to call TAP for more information. (Ask for David Aaron or 
Daniel when you call TAP at774-6877.) 
We are in the process of finding t-shirts for the parade volun-
teers and need a tally of how many TAP marchers to expect. 
Vehicles may be arranged for those who cannot walk the parade 
route. We hope you can join us! 
TAP Office Closed May 20th 
The AIDS Project's office in Portland will be closed on 
Thursday, May 20th for painting. We will resume normal 
business hours the next day. 
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by the way 
by Mike Martin 
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back to school special ,,_ 
Going back to school was a lot more fun than I had 
expected it to be. The AIDS Project was recently invited to do 
some HIV prevention education at South Portland High 
School. So Gloria Leach, TAP's Community Educator; 
Declan Buckley, TAP's Outreach Worker; Doug Eaton, 
TAP's Hotline and Counseling and Testing Coordinator; and 
I headed out to South Portland High where we spoke to the 
four classes individually (freshman, sophomores, juniors, 
and seniors) in their very impressive auditorium. Each class 
has about 200 students. 
This was the first time I had been asked to speak with 
the folks from TAP's Prevention Education department. 
Mostly I have spoken to healthcare students and profession-
als, from Biddeford to Orono, in conjunction with the AIDS 
Consultation Service of Maine Medical Center. So, not only 
was I facing a new audience, but a new cast as well. I am 
pleased to say that we hit it off all around. 
As the kids straggled into the auditorium, some of 
them horsing around, some of them looking decidedly wary, I 
noticed some of them were wearing red ribbons, in support of 
AIDS awareness. Then the principal introduced us and 
Gloria led the way. Gloria is 65 years old and so she began her 
talk by saying, "A lot of you are probably wondering why 
your grandmother is talking to you about HIV!" It's a great 
icebreaker, and the kids all laughed. 
And then for an hour and fifteen, with each class, 
Gloria, Declan, Doug and I talked to the kids about HIV and 
AIDS. The school allowed us to be very frank with the kids, 
and the kids really paid attention. The invitation to speak 
came about because students and teachers at the school let the 
principal know that they wanted to go further in their HIV 
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education than what they were learning in health classes. We 
certainly went further. Gloria has a very straight-forward 
approach to HIV education and she set the tone for these 
sessions. 
Of course, the hope is that by reaching over 800 kids, 
we will make a dent in the epidemic of HIV. Studies indicate 
that young, gay men are slacking off when it comes to safer 
sex. And, in youth in general, there is a growing compla-
cency about safer sex practices, though, by the curiosity and 
attention, we received at South Portland High, you wouldn't 
know it. These kids seemed very aware and eager to know 
more. 
After each session, the kids were invited to come up 
to us and ask questions if they had any. Mostly the kids who 
came up to me just wanted to tell me about a relative of their's 
who had HIV, or had died of AIDS and for whom they had 
made a quilt panel. 
In a time when Maine high schools are feeling the 
effects of the shootings and bombings at Columbine High in 
Colorado, being safe is on kids' and teachers' minds. The 
principal even said in her introductions that the reason for 
having The AIDS Project come to the school was all about 
helping the kids be safe and healthy. 
The greatest challenge in the epidemic is to reach out 
to youth with information and real stories about HIV and 
AIDS, to help them make responsible decisions about their 
sexual practices. I was very impressed with Gloria, Declan, 
and Doug, and with the students and staff at South Portland 
High. And I can't help but think that the message got through 
to a lot of those very attentive students. The message being 
that information is power -- power to stay healthy. • 
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A Safe, Healthy, and Friendly 
Meeting Place for 
HIV-positive People 
in Southern Maine. 
by Billy, Johnathan, and Judy 
The Wellness & You Program 
at the University Of New England, 
Westbrook Campus. 
When people hear the name of this program, images of kindergarten field trips and basket weaving may come to 
mind, but Wellness & You, sponsored by the University Of New England and the AIDS Project, is anything but a 
walk in the park. This nationally-recognized program for people living with mv offers many unique opportunities. 
Working out has been proven to help bolster the immune system. Statistics show that maintaining healthy 
muscle mass will increase an individual's quality oflife. This is a program about individualized health care for those 
living with HIV. It can include everything from stretching exercises to free weights, cardiovascular training to HIV-
related nutritional information, as well as introductions to alternative therapies such as yoga, massage, Tai Chi, 
Reiki, and self-defense . 
Wellness & You provides a safe meeting place. The participants are all people living with HIV. Attending 
provides the opportunity for HIV-positive people to help each other combat the isolation of being positive in the 
state ofMaine. Men and woman, straight and gay are all together sharing their growth through healthy channels. 
A special thanks to the University OfNew England for providing such a safe and comfortable atmosphere. Also, 
thanks to Judy Vezina, the program's coordinator, for contributing to this well-supervised experience. 
Some participants have commented that, "the Wellness program and Judy saved my life," and "it's one of the 
best experiences I have had in the state of Maine. "For better health and as an alternative meeting place with a safe 
and comfortable environment, the Wellness & You program can't be beat! 
Wellness & You is currently accepting new members, for more information, please con-
tact: Daniel Schnorbus, TAP's Client Services Coordinator, at The AIDS Project in Portland 
at 774-6877 or Denise Ferer, TAP's York County Case Manager at The AIDS Project in 
Kennebunk at 985-8199. • 
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Wellness Participants' Photos. 
(Top) Ron Goben does some crunches. 
(Bottom, Left to Right) Ron rides the stationary bike. Neal Brown is 
checked out by Wellness Coordinator Judy Vezina. Neal works with some 
of the equipment available at UNE. · ,-.lt~ -Page Three 
HIV Medical Science HIV Medical Science 
Lipidostrophy: Glaxo Researchers Suggest Abnormal Body-Fat Distribution in HIV-1-lnfected 
Mechanisms, Publish Data Children on Antiretrovirals 
AIDS Treatment News (03/19/99) Lancet (04/ 10/99) 
At the recent conference of retroviruses in Chicago, 
researchers from Glaxo Wellcome presented hypotheses 
and related data on lipodystrophy in HIV-infected patients, 
which many scientists believe is associated with protease 
inhibitor therapy. Some patients have shown high 
cholesterol and triglyceride levels, abnormal fat deposits, 
and the development of insulin resistance. Studies show 
that saquinavir, ritonavir, and nelfinavir greatly reduce the 
development of fat cells from stem cells in vitro. The drugs 
also increased the metabolic destruction of fat in existing 
fat cells. The loss of deposited fat in the body could lead to 
high levels of low-density lipoprotein cholesterol and 
triglycerides. Another proposed mechanism involves 
retinoids, compounds that are related to vitamin A. When 
protease inhibitors and retinoids were combined, complex 
reactions were observed in certain genes. lndinavir may 
cause some effects resembling lipodystrophy by changing 
retinoid signaling. If the mechanism is correct, patients 
receiving indinavir may be at risk if they also take vitamin A 
supplements. 
Liposuction for Protease-Inhibitor-Associated 
Lipodystrophy 
Lancet (04/10/99) 
Mexican researchers presented the case of a 46-
year-old man who used liposuction to treat the 
lipodystrophy that developed as a result of his use of 
saquinavir and nelfinavir. The man, who was diagnosed 
with HIV in 1989, had been taking a combination of 
zidovudine, zalcitabine, and saquinavir for about a year 
when he observed a continued thickening of his neck. The 
cocktail was switched to nevirapine, nelfinavir, and 
didanosine, but more than a year later he developed a 
buffalo hump as a result of abnormal fat accumulation in the 
area. Until something else is developed, the researchers 
note that liposuction may be an acceptable treatment for 
abnormal fat deposits, which may play a role in non-
compliance with antiretroviral regimens. 
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Researchers from the Boston University School of 
Medicine investigated the prevalence of abnormal body-
fat distribution in HIV-I -infected children. The authors 
based their data on a survey sent to all pediatric AIDS 
Clinical Trial Groups and National Institute of Child Health 
and Human Development sites between March and 
August of last year. Of the 55 sites responding, 16 
reported at least one instance of abnormal fat distribution. 
A total of 1,644 out of 2, 713 children on antiretroviral 
therapy were taking protease inhibitors. One percent 
experienced abnormal fat distribution; 0.4 percent of 
those who did were not taking protease inhibitors, while 
1.5 percent were taking the drugs. Nearly two-thirds of 
the children with abnormal body fat were female, more 
than 40 percent were African-American, and the average 
age was 10.9 years. At the time of reporting, the mean 
viral load in children with abnormal body fat was 98,000 
copies, and the mean CD4-cell count was 367 cells. The 
researchers note that future research should present a 
standardized definition of abnormal body fat distribution, a 
comparative analysis of risk factors, evaluations of 
endocrine abnormalities, and correlations with particular 
therapies. 
HIV-2 Infection Not Protective Against HIV-1 Infection 
Reuters (04/21/99) 
New research suggests that infection with HIV-2 
does not prevent HIV-1 infection. Because the two strains 
have a similar transmission route, it had been thought that 
immune response to HIV-2 would prevent subsequent HIV-
1 infection. However, a study in the April 16 issue of AIDS 
found that women seropositive for HIV-2 were more likely 
to generate evidence of infection with HIV-1 than women 
seronegative for HIV, although the difference between the 
groups was not statistically significant. In a second study 
in the same journal, Dr. Hans Norrgren of the University 
Hospital in Lund, Sweden, found that HIV-2-positive 
individuals tended toward a higher risk of acquiring HIV-1 
than their seronegative counterparts. 
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HIV Medical Science 
AIDS Lifts Danger of Cancers 
Sydney Morning Herald Online (05/01/99) 
New findings published in the journal AIDS indicate 
that people with AIDS are more at risk of contracting 
aggressive cancers. According to Dr. Andrew Grulich, 
primary author of the study, AIDS patients are more likely to 
get cancer of the skin or lip, as well as Hodgkin's Disease. 
The study examined all cases of cancer until 1996 among 
people diagnosed with AIDS between 1980 and 1993 in 
New South Wales. The researchers noted that among more r 
than 3,600 AIDS diagnoses, there were 873 cases of 
cancer, including 62 not usually linked to AIDS. \ 
' 
Steroids Found to Help Patients Build Muscle 
New York Times (04/14/99) 
Two anabolic steroids provided renewed strength to 
patients weakened from kidney dialysis and from weight 
loss due to HIV infection, according to two separate studies 
in an issue of the Journal of the American Medical 
Association. 
While more information is needed about dosage and 
duration oftreatment, dialysis patients given steroids made 
with nandrolone decanoate increased their average nonfat 
body weight by 5.5 pounds more than the placebo 
recipients, according to University of California at San 
Francisco assistant professor Dr. Kirsten L. Johansen. The 
second study, led by UCSF researcher Dr. Alison Strawford, 
found that of 22 HIV-infected patients put on a modest 
resistance weight lifting program, the 11 who received the 
synthetic steroid oxandrolone gained an average of 16 
pounds versus eight pounds for the placebo group. The 
researchers observed, however, a significant decline in 
high-density lipoprotein cholesterol in the steroid 
recipients. 
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HIV Drug News 
Researchers Discover AIDS Cocktail Can Rebuild 
Immune System 
Minneapolis Star Tribune Online (05/07/99) 
Dr. Zhi-Qiang Zhang and Dr. Ashley Hasse, both 
researchers at the University of Minnesota, have found that 
highly active antiretroviral therapy (HAART) may help the 
immune system regenerate itself. The study, published in 
Proceedings of the National Academy of Sciences, details 
how Zhang and Hasse tracked the regeneration of the 
follicular dendritic cell (FDC) network. The FDC network, a 
key part of the immune system, is often targeted and wiped 
out by HIV. Previously, researchers thought that once the 
FDC network disappeared, it was gone for good; however, 
the new findings indicate that the protective cells of 
patients on HAART increased in number, approaching levels 
of HIV-negative individuals. Study co-author Dr. Tim 
Schacker cautioned, however, that the study involved only 
individuals who responded well to HAART. 
lmmunex Says Leukine Extends AIDS Therapy 
Reuters (05/04/99) 
The cancer drug Leukine is useful in helping to extend 
AIDS patients use of antiretroviral drug cocktails, according 
to the drug's maker, lmmunex. Data from the stage Ill study 
indicated Leukine stimulates the immune system, 
suppresses the virus, and lowers the incidence of all 
infections and death. Unlike antiretroviral drugs that directly 
attack the virus that causes AIDS, Leukine prevents HIV 
from entering uninfected cells, as well as rejuvenating cells 
weakened by the disease's progression. lmmunex noted 
that 83 percent of the 57 patients in the study with 
undetectable viral levels maintained that undetectable level 
after 24 weeks of Leukine therapy, versus 54 percent of 
patients who were given placebo. 
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HIV Drug News 
HAART Failure Is Common in Clinical Practice 
Reuters (04/19/99) 
San Francisco researchers report that in clinical 
practice, many HIV patients who receive highly active 
antiretroviral therapy with a protease inhibitor will 
encounter virologic failure within one year. However, the 
researchers, from San Francisco General Hospital and the 
University of California, note that cases of immunologic 
failure were rare during at least the first 12 months. The 
study involved 337 patients, who all received at least 16 
continuous weeks of HAART, and revealed that about half 
the patients had plasma HIV RNA loads under 500 copies 
after 48 weeks. The findings were published in the April 16 
issue of AIDS. 
TAP's York County 
Clients Can Access 
The Internet 
York County Clients of TAP can 
use the computer at its 
Kennebunk office to access the 
internet. Call Denise Ferer at 
985-8199 to set up a time to 
use the computer. 
Also, clients can now e-mail 
TAP's Kennebunk office at: 
www.tap2@mail.javanet.com 
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Why AIDS? 
Science News (03/27/99) 
Despite millions of dollars tor research 
over the past 15 years that has produced many 
powerful treatments tor AIDS, scientists have 
yet to unravel the mystery of how HIV invades 
the immune system and causes it to cease 
functioning properly. While many scientists 
initially believed that HIV attacked the immune 
system by directly targeting helper T cells, 
immune cells also known as CD4 cells, and 
eliminating them, several new studies suggest 
HIV uses a different mechanism to disrupt CD4 
cells that is more important and may provide 
more insight about potential treatments or 
vaccines. Developed in 1995, one of the first 
successful theories suggested that HIV 
destroys CD4 cells, which forces th~ immune 
system to produce more CD4 cells that then 
support the spread of the virus rather than 
protect against it. Researchers believed the 
immune system would eventually run out of 
steam and stop producing CD4 cells. However, 
a study published in January's Nature Medicine 
indicated that antiretroviral therapy was 
responsible tor an increase in the production of 
CD4 cells above normal levels, confirming that 
HIV's impact on CD4 production was as 
important as its impact on CD4 destruction. A 
more recent theory reported in January's 
Journal of Immunology showed the virus may 
force many CD4 cells to leave the blood and 
enter certain tissues and lymph nodes where 
they are destroyed or self-destruct. The theory 
was confirmed in mice but still needs to be 
tested in humans. 
Source for some of the information in this 
newsletter include: 
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Experts are unable to explain why, and few if any can 
understand the reasons when provided, but a number of 
recent studies indicate there has been an increase in the 
number of gay men who regularly engage in unprotected 
anal sex, also known as barebacking. According to a survey 
by the Centers for Disease Control and Prevention about gay 
male sexual habits in San Francisco, 60.8 percent of men 
surveyed in 1997 said they always used a condom, 
compared to 69.9 percent in 1994. And 68 percent of those 
who participated in unprotected anal sex with multiple 
partners said they did not know the HIV status of all their 
partners. For many gay men, the primary justification for 
engaging in such risky behavior is that they do not see HIV 
infection as a threat to their lives-a contention the scientific 
community says is absolutely baseless. 
Some experts investigating this potentially deadly 
decision also note barebacking is seen by some as a way to 
celebrate risk, while others point out that young gay men 
living today automatically link being gay with having AIDS. 
In younger populations, the problem is exacerbated by the 
fact that many do not know a person who has died from 
AIDS. The issue of barebacking is particularly difficult to 
deal with for those trying to prevent HIV transmission and 
who fear the trend spread could convince others it is okay to 
have unprotected sex. 
Teen-Agers Can Curb AIDS With Knowledge 
Sun Herald Online (04/19/99) 
Half of the new HIV cases in the United States involve 
people under the age of 25. The causes for this have been 
attributed, in part, to a lack of awareness and risky behavior. 
Also, teenagers are having sex earlier than before, with 77 
percent of girls and 86 percent of boys having had sex by 
age 20. The three main routes to HIV infection are sexual 
intercourse, intravenous drug use, and blood transfusions, 
although blood testing has made this very rare. In 
Mississippi, the group Pioneers for AIDS Counseling and 
Training (PACTI encourages HIV education by sending 
teenagers to speak about the issue to youth groups and 
clubs. "We show videos and talk about some things that 
make people uncomfortable, but it's so important," notes 
PACT founding member, 16-year-old Natalie Davidson. 
Checking in With David Ho 
Rolling Stone (04/29/99) 
In an interview with Rolling Stone, renowned AIDS 
researcher Dr. David Ho discussed the state of the AIDS 
epidemic. Participants at the International AIDS Conference 
in Geneva last summer heard reports that the costly 
combination drug therapy made famous by Ho does not 
work for everyone, has stopped working in some, or has 
significant side effects. But Ho points to the significant 
decreases in AIDS-related deaths in the United States and 
Europe in the past several years as evidence of progress. 
He views a cure as a long-term goal, but sees the possibility 
of the immune system being able to control the virus 
without drugs as potentially much closer. Ho sees HIV 
education and the development of a vaccine as two key 
prevention measures. The researcher noted that AIDS 
needs to become a national priority, citing the soaring rates 
of infection in countries like South Africa, India, and China 




A New Foe in the Fight Against AIDS 
Boston Globe Online (04/21/99) 
In a commentary, Larry Kessler, of the AIDS Action 
Committee in Boston, cites a new attitude of compla-
cency as the greatest hurdle facing those battling AIDS. 
This complacency can be seen in reduced AIDS funding 
and risky sexual practices. To fight the complacency, 
Kessler points out that efforts should be redoubled in the 
areas of prevention and in keeping HIV-infected individuals 
healthy. He also suggests that clean needle programs and 
education programs must be emphasized if the spread of 
the disease isto be curbed. 
Doctors Must Report Names of Those Who Test HIV-
Positive 
Topeka Capital-Journal Online (04/16/99) 
Kansas Gov. Bill Graves signed into law a measure 
that would force physicians and laboratories to report to 
the state Department of Health and Environment the 
names and addresses of individuals testing positive for 
HIV. Previously, only those diagnosed with AIDS had their 
names reported to the state; cases of HIV were reported 
only in terms of the number of infections. Under the new 
bill, the secretary of the state health department would be 
required to establish rules regarding the confidentiality of 
data about HIV-infected individuals that are as demanding 
as those employed by the Centers for Disease Control and 
Prevention. 
Ministers Seek to Cut AIDS Toll Among Blacks 
Los Angeles Times Online (04/22/99) 
A coalition of ministers will be working with the 
state of California in an effort to fight AIDS in the African-
American community. In the United States, AIDS is the 
No. 1 killer of African Americans between the ages of 25 
and 44. The new Statewide Church Advisory Board will 
provide materials, provide technical help, and a ministry 
kit designed to teach religious leaders about the illness 
and how to incorporate it into their sermons. The hope of 
the ministers is that they will be able to disseminate 
knowledge of the disease to their congregation, and so 
help to cut incidence of the disease. 
UK Sees Record HIV Infection Levels in 1998 
San Jose Mercury News Online (04/13/99) 
New statistics estimate that the number of new HIV 
infections in the United Kingdom rose to almost 3,000 last 
year, the highest rate since the epidemic began. The 
Terrence Higgins Trust, which made the predictions, said 
the findings reflect a need for greater safe sex education. 
The charity has yet to compile the final statistics for 1998, 
but noted that the number of HIV-infected individuals in 
the United Kingdom could increase by 50 percent to about 
27,000 by 2003. A MORI poll on attitudes toward sex 
revealed that many groups were still unaware of the risks 
of unprotected intercourse, the trust said. 
HIV Drug News 
Supervised Breaks From HIV Meds May Strengthen 
Immunity 
MSNBC Online (05/04/99) 
Investigators, fearing that the new antiviral 
medications may be a temporary fix, are exploring the idea 
of killing HIV with the body's natural defenses. Some 
researchers also believe that genetic engineering may help 
the body fight HIV. "One way to do that is to try to take the 
cells that the patients have and now refocus them so they 
can do what the virus has destroyed." John Ceravsky, an 
American patient diagnosed with HIV, stopped taking his 
medication at the recommendation of his doctors last 
February. Although he has had to return to his medications 
because the virus drove his T-cell count down, doctors note 
that he can go longer and longer without medication. 
HIV Heresy 
New Scientist (03/27/99) 
While the use of so called drug cocktails has greatly 
improved the lives of many HIV-infected patients, some 
AIDS researchers now are proposing that patients take 
carefully scheduled "holidays" from their combination 
therapies to let the body's own immune system fight the 
disease. Researchers advocating this approach believe that 
suspending use of the drug cocktail, which interrupts two 
key viral enzymes, will allow the body to create a strong 
cytotoxic T lymphocyte (CTLI response that will control the 
virus. 
At the recent Conference on Retroviruses and 
Opportunistic Infections, Franco Lori of the Research 
Institute for Genetic and Human Therapy presented the 
case of a patient in Bertin using a triple-drug combination 
that was stopped twice and ultimately suspended who 
showed negligible HIV levels after two years. A study by 
Lori involving monkeys found a similar result at 145 days 
after the animals had taken several monitored drug 
holidays. Despite the animal study and other anecdotal 
evidence of similar success, researchers emphasized that 
randomized controlled trials were needed to be sure the 
approach was effective in humans and did not lead to drug 
resistance. If the strategy does prove effective, researchers 
said it may be possible for some patients to suspend drug 
treatment indefinitely. 
Successful Treatment of Pediatric HIV-Related CMV 
Encephalitis Reported 
Reuters Health Information Services (04/16/99) 
Swiss researchers report that combining ganciclovir 
treatment with highly active antiretroviral therapy can 
resolve the cerebral lesions and clinical symptoms of 
pediatric HIV-related cytomegalovirus encephalitis. Until 
now, only one case of successful treatment of pediatric HIV-
related CMV encephalitis has been reported; however, Dr. 
Christoph Rudin, of the University Children's Hospital in 
Basel. and colleagues detail in April's Pediatric Infectious 
Disease Journal the second successful treatment of the 
disease. The researchers found that within weeks of 
receiving the new treatment, the subject's clinical and 
neurological symptoms improved remarkably. According to 
the researchers, the effectiveness of the treatment seems 
to rest on its interdisciplinary approach, which utilizes 
social and psychiatric support in addition to the prescribed 
medical treatment. 
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AIDS Hotline is Seeking Volunteers 
Doug Eaton, Hotline Coordinator, is seeking applications 
from qualified volunteers to fill vacancies on the Hotline. Doug 
feels that using clients as Hotline workers would enhance the 
service that the Hotline provides to those wanting information 
about transmission, safer sex, and referrals to testing sites. 
If you would like to talk with Doug about this opportunity, 
give him a call at 775-1267 or 1-800-851-2437. If you get the 
answering machine, please leave a message and Doug will get 
back to you. 
HIV and Women 
Antiretroviral Therapy Reduces HIV Levels in Female 
Genital Tract 
Reuters (04/09/99) 
Correlations between plasma HIV levels and HIV 
vaginal load have been reported, by researchers from the 
CDC, along with major reductions in both after antiretrovial 
therapy. The researchers say that successful antiretroviral 
therapy may reduce ''the risk of perinatal and heterosexual 
transmission by lowering vaginal virus load." The group 
used a quantitative-competitive reverse-transcriptase 
polymerase chain reaction assay to assess the correlation 
between plasma and genital tract HIV levels. 
Increased STD Risk Seen in HIV-Infected Women 
Reuters (04/13/99) 
Research published in the March issue of Sexually 
Transmitted Diseases indicates that HIV-infected females 
have a higher rate of lower genital tract infection. The study, 
conducted by the Women's lnteragency HIV Study, also 
revealed that sexually transmitted disease symptoms 
become more noticeable over the course of HIV infection. 
According to the authors, HIV-infected women were more 
likely than HIV-negative women to have a history of STD's, 
excluding bacterial vaginosis and chlamydia. To reduce the 
occurrence of lower genital tract symptoms and possible 
sequelae of STDs, the researchers recommend that women 
infected with HIV receive careful gynecologic exams. 
HIV-Infected Mother Loses Fight for Baby 
Los Angeles Times (04/21/99) 
On Tuesday, Juvenile Court Judge Maurice Merten 
refused to give up state custody of an infant born to an HIV-
positive woman who wants to breast feed. "The parents 
may choose to run that risk with the child, but the court may 
second-guess that decision," Judge Merten said. The four-
month-old boy will be allowed to live with his family, but a 
caseworker from Oregon's Office for Services to Children 
will visit periodically to ensure that the order is being 
fulfilled. Kathleen Tyson's case rested on the contention that 
HIV does not cause AIDS and cannot be transmitted through 
breast milk; however, witnesses for the state testified that 
breast milk from an infected mother has a very high risk of 
virus transmission. 
HIV Vaccine News 
Single-Strain Vaccine Danger 
Scientific American (04/99) 
Single-strain vaccines may increase an individual's 
risk of contracting disease, according to a new model 
described in the January issue of Proceedings of the 
National Academy of Sciences. Viruses often exist in 
multiple strain complexes; antibodies to a single strain of a 
virus are usually active against related strains. 
Researchers found, though, that certain viruses react to 
antibodies of closely related strains by mounting a more 
severe attack on the host. In this scenario, vaccines 
against single strains--such as some that are under 
development against HIV--could result in increased risk of 
disease. 
After 17 Healthy Years, Hope of 'Safe' H.I.V. Dies 
New York Times (04/20/99) 
Australian researchers, studying a small group of 
individuals who have been infected with HIV for years 
without any AIDS symptoms, recently ended their hope of 
developing a vaccine from the naturally weakened live 
virus strain. The patients, who contracted HIV via 
transfusions from one blood donor, have lived with HIV for 
up to 17 years. However, the donor was diagnosed in 
February with an AIDS-related infection of the brain and 
spinal cord, and two patients have weakened immune 
systems, although they have not become sick. The strain 
of HIV was weakened by a natural deletion of net. The 
researchers will continue to study the three infected 
individuals who are still healthy. 
Mortality Rising in Developing Countries Due to AIDS, 
Environmental Limits 
Reuters (04/12/99) 
A new study from the concludes that HIV, falling 
water stocks, and shrinking crop land are contributing to 
rising mortality rates in the world's poorest nations. Lester 
Brown, co-author of "Beyond Malthus, Nineteen 
Dimensions of the Population Challenge," notes that the 
HIV epidemic is soaring out of control in some developing 
nations, with infection rates as high as 20 percent to 25 
percent in countries like Zambia and Botswana. Short of a 
miracle, 20 percent to 25 percent of the adults in nations 
with high HIV infection rates will die during the next seven 
years, Brown forecast. 
HIV Drug News 
Study AIDS Drugs Long-Term, Makers Told 
Toronto Globe & Mail (05/04/99) 
Dr. Julio Montaner, co-director of the Canadian HIV 
Trials Network, and treatment pioneer Dr. Jeep Lange, 
recently criticized the pharmaceutical industry for 
neglecting to study the long term side-effects of AIDS 
drugs. Dr. Montaner said that pharmaceutical companies 
should be required to do follow-up tests of their medication 
as part of the approval process for the drugs. Increasingly, 
some patients who have been using the powerful new AIDS 
therapies have developed premature heart disease, 
lipodystrophy, and liver disease. "What we have is a 
tremendous improvement over what we used to have," Dr. 
Lange said, "but we must find ways to reduce life-
threatening toxicity." 
Drugs May Cause AIDS to Lurk in Cells 
Washington Post (04/27/99) 
New research in the journal Nature Medicine 
estimates that HIV can hide undetected in people taking 
antiviral drugs for up to six decades. The drugs can reduce 
the body's levels of HIV to undetectable levels, but they 
cannot eliminate the hidden reservoirs of HIV in cells. The 
researchers, led by Robert Siliciano of Johns Hopkins 
School of Medicine, studied 34 HIV-infected adults who 
were all taking virus-suppressing treatment. Based on 
samples of "resting" CD4 T cells in the patients' blood, the 
researchers estimated how many cells were concealing 
HIV at various points of treatment, calculated how long it 
would take this reservoir of infected cells to die, and came 
up with an estimate of about 60 years. 
FDA Approves an AIDS Drug From Vertex 
Wall Street Journal (04/ 19/99) 
The U.S. Food and Drug Administration granted on 
marketing authorization to Vertex Pharmaceuticals for 
Agenerase, the fifth drug targeting HIV's protease enzyme 
that has been approved for the treatment of AIDS. Vertex 
developed the drug, which will be marketed by Glaxo 
Wellcome, using technology licensed from Monsanto's G.D. 
Searle unit. One advantage of Agenerase over other 
approved protease drugs is that patients need take it only 
twice a day, rather than three times a day; but users must 
consume eight pills of Agenerase at each sitting, compared 
to two to six when using the other drugs. 
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Co111e On Out for a Walk! 
The Outdoor/Wellness Group is continuing throughout the summer! The locations for the walks will be giiven to 
you when you contact Denise Ferer, Case Manager, in TAP's York County Office by calling 985-8199. All those 
interested can contact Denise directly! 
This group has been put together so that you can be outside enjoying yourself and having fun while meetirng new 
people! Trips are held one Saturday for each of the summer months from 11 :30 a.m. to approximately 2 p.m. Bring a 
lunch, a pair of comfortable shoes and your good spirits! Transportation is provided, if needed. 
The dates for the summerwalks are: 
June 12 (rain date - June 19) 
July 10 (rain date-July 17) 
August 14 (rain date -Aug. 21) 
SUPPORT GROUPS 
FOR PEOPLE INFECTED PROJECT PROJECT PROJECT 
AND AFFECTED BY HIV/AIDS 
MONDAYS 
Time: 5:00 p.m. to 6:30 p.m. 
Group: HIV and Substance Abuse 
Location: Portland, The Meeting Room, Suite 632. 
Contact Carolyn Curtis at TAP at 774-6877, or David 
Gordon at Portland Public Health at 874-8784. 
TUESDAYS 
Time: 10:30a.m. to noon 
Group: HIV Infected/Affected Drop-In Support Group 
A meeting for people living with and affected by the virus. 
Location: Portland, TAP. The Meeting Room, Suite 632. 
Contact Susan Parr at TAP at 77 4-6877 for more info. 
THURSDAYS 
CLIENT SERVICES 
MEDICAL ASSISTANT FUNDS 
An important reminder to clients: 
There are funds available to TAP clients with financial need 
for the following items: Routine Dental Care, Routine Eye 
Care and Eyeglasses, Vitamin Supplements, Non-
Prescription Skin Care Products, and Non-Medicaid 
Medication Co-pays. 
There is a dollar limit to how much a client can receive in any 
fiscal year. Contact your case manager for assistance. 
WELLNESS AND YOU PROGRAM 
A stress reduction and physical activity program 
Time: 10:00 a.m. to 11 :30 a.m. designed for people living with HIV/AIDS. In this program 
Group: HIV Infected/Affected Drop-in Group individuals can participate in a variety of supervised 
A TAP-sponsored meeting for people physical activity, education, and specialized stress 
living with and affected by HIV/ AIDS in southern Maine. management segments. Contact Daniel at TAP at 77 4-
Location: Sanford, Unitarian Church, located at the comer of 6877 for more information. 
Main St. (Rte. 1091 and Lebanon St. (Rte. 2021. 
Contact Getty Payson at TAP at 985-8199 for more info. 
Time: 12 noon 
IMMEDIATE SEATING 
For free tickets to area events as they become available, 
sign up for "Immediate Seating." Call Daniel at TAP at 774-
6877 for more information. 
THE MEETING ROOM 
This room is used by TAP in Portland for support groups, 
counseling and testing, and some client/case manager 
meetings. Located in Suite 632, it provides more privacy for 
people served by TAP. 
Enter from the High Street side of the building. 
I.V LEAGUE 
Meetings of the 1.V. League support group are held on 
Thursdays from 10:00 to 11 :30 a.m. at First Parish Church 
at 425 Congress St. in Portland. (Use the right side entrance 
and ring the bell.I This group is for IV Drug Users past and 
present. 
For more information, call Steve Farrell at 874-8775. 
Group: Open Lunch for TAP Clients/Staff 
An informal luncheon gathering ofTAP staff and clients. 
Location: Portland, TAP. Conference Room. 
FOR YOUR INFORMATION 
Contact Daniel Schnorbus atTAP at 774-6877 for info. 
Time: 5:30 p.m. to 7:00 p.m. 
Group: People Uving with HIV/AIDS 
A drop-in support group for anyone with HIV/ AIDS. 
Location: Portland, TAP. The Meeting Room, Suite 632. 
Contact Susan Parr at TAP at 774-6877 for more info. 
>>>>New Group<<<< 
When: Day and Time to be announced 
Group: Expressive Therapy 
Explore your creativity through art, music, movement. 
Location: Portland, The Meeting Room, Suite 632. 
Contact Susan Parr at TAP at 774-6877 for more info. 
AIDS HOTLINES HIV WEBSITES TAP ON·LINE 
Questions about HIV/AIDS? 
Call toll-free 








for info on HIV and AIDS. 
Visit our new website at: www.aidsproject.org 
To e-mail The AIDS Project, 
send your message along to: 
tap@aidsproject.org (Portland! 
or tap2@mail.javanet.com (Kennebunk! 
For more information about programs 
at The AIDS Project, call 774-6877. 
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For more information, call Steve Farrell at 874-8775. 
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tap@aidsproject.org (Portland! 
or tap2@mail.javanet.com (Kennebunk I 
For more information about programs 
at The AIDS Project, call 774-6877. 
In The Affirmative © May 1999 from Bald Man Publishing for The AIDS Project, Portland, ME 
